Lead Product(s) : Tolinapant
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : US FDA has granted orphan drug designation for the company’s novel, orally administered non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP), tolinapant , for the treatment of T-cell lymphoma.
Product Name : ASTX660
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 31, 2020
Lead Product(s) : Tolinapant
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
